Researchers at Duke University reported that neoadjuvant anti-PD-1 antibody therapy combined with RT (20 Gy in a single fraction) followed by surgery significantly improved local recurrence-free survival (LRFS) (p = 0.04) and DFS (p = 0.01), compared with surgery plus isotype control antibody in the p53/MCA sarcoma model [49]. Here, PDCD1 is linked to sarcoma.